MedAvail Holdings Inc. filed SEC Form 8-K: Other Events

$MDVL
Retail-Drug Stores and Proprietary Stores
Consumer Staples
Get the next $MDVL alert in real time by email
medavail-20231114
0001402479false00014024792023-08-172023-08-17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2023
MEDAVAIL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware001-3653390-0772394
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer
Identification Number)
4720 East Cotton Gin Loop, Suite 220,
Phoenix, Arizona 85040
(Address of principal executive offices)(Zip Code)
(877)830-0826
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareMDVLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01. Other Events

MedAvail Holdings, Inc. is unable to file its Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended September 30, 2023 by the November 14, 2023 filing deadline. We require additional time to complete the preparation and corresponding review of our condensed consolidated financial statements as of and for the quarter ended September 30, 2023. During the quarter ended September 30, 2023 and in the subsequent period during which we prepare our financial statements and related disclosures for inclusion in the Form 10-Q, we have experienced delays in new partner contracting, the deployment of our MedCenter™ products by our partners and in integration services for contracted MedCenter units. The cumulative effect of these delays, in the absence of favorable developments in the future or a supplemental capital raise within the next twelve months, could have an adverse impact on our projections for liquidity during 2024. These potential adverse effects on our liquidity require us to perform more extensive and complex procedures to assess the potential impact of these effects on our financial statements and the impact of liquidity financing options, for which we need additional time prior to filing our Form 10-Q.

Forward-Looking Statements

Certain statements in this Report, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our projections for liquidity, the potential impairment of long-lived assets and the timing for filing the Form 10-Q. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause actual results to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to risks related to completion of our condensed consolidated financial statements for inclusion in the Form 10-Q. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates concerning those or other forward-looking statements.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 MEDAVAIL HOLDINGS, INC.
  
Date: November 14, 2023
By:/s/ Ramona Seabaugh
  
Ramona Seabaugh
Chief Financial Officer

Get the next $MDVL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MDVL

DatePrice TargetRatingAnalyst
More analyst ratings

$MDVL
Press Releases

Fastest customizable press release news feed in the world

See more
  • MedAvail Announces Agreement with New Orleans-Based St. Thomas Community Health Centers for Deployment of Two M4 MedCenters

    PHOENIX, Nov. 28, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with New Orleans-based St. Thomas Community Health Centers for the deployment of two M4 MedCenter kiosks. St. Thomas operates eight Federally Qualified Health Centers (FQHCs), providing affordable health care to underserved communities across the New Orleans metropolitan area. "We are very excited to announce this new agreement with St. Thomas, building upon our existing infrastructure in the New Orleans area and growing our presence in the FQHC partner channel, where we see significant long-term gro

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

    PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), an innovative pharmacy technology company, announced today that on November 16, 2023, the Company received a delinquency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to have timely filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission. The delinquency notification letter provides that, under Nasdaq rules, the Company now has 60 calendar days to submit

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • MedAvail Announces Agreement with ASP Cares for Deployment of Ten M4 MedCenters

    Initial three deployments to be completed in early 2024 at ASP Cares Pharmacy in Las Vegas Agreement repsents expansion of successful relationship with Dallas-based Oak Lawn Pharmacy PHOENIX, Nov. 17, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, announced today that it has entered into an agreement with Pharmacy Fund 1 for the deployment of ten M4 MedCenter kiosks, which will be serviced by ASP Cares Pharmacy. Pharmacy Fund 1 also operates Oaklawn Pharmacy, which is a current MedAvail partner in Dallas, Texas. Per the terms of the agreement, the first three MedCenters are planned to be deployed at First Person

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$MDVL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MDVL
SEC Filings

See more

$MDVL
Leadership Updates

Live Leadership Updates

See more
  • MedAvail Strengthens Leadership Team

    MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail") a technology-enabled pharmacy company, today announced the appointment of industry leaders Steven Hess to Executive Vice President, General Manager, of SpotRx and Bob McClune to Senior Vice President of Data and Analytics. "We are pleased to have Steven join our senior leadership team. Steven's extensive pharmacy experience across retail and specialty will be integral in leading our strategies to drive profitable growth and optimize our SpotRx hub pharmacy and MedCenter enabled clinic operations. We also welcome Bob to MedAvail to lead our efforts in optimizing and accelerating data exchanges with our clinic partners," said Mark Doerr, Chi

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • MedAvail Announces Changes to Executive Management and Board of Directors; Preliminary Fourth Quarter and FY 2021 Results

    MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), a technology-enabled pharmacy company, today announced that Mark Doerr, RPh, has joined the company as chief executive officer ("CEO") and director, effective January 10, 2022. Mr. Doerr succeeds Ed Kilroy, who retired as CEO and from the board of directors and is moving into an advisory role through March 31, 2022. The company also announced changes to its board of directors and reported preliminary fourth quarter and full year 2021 revenue results. Gerard van Hamel Platerink has stepped down as chairperson of the board of directors. Mr. van Hamel Platerink has served on MedAvail's board of directors since June 2012. He is succeeded by c

    $MDVL
    $ME
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MedAvail Appoints Ramona Seabaugh as Chief Financial Officer

    MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail" or the "Company"), a technology-enabled pharmacy company, today announced the appointment of Ramona Seabaugh as Chief Financial Officer effective immediately. As a key member of MedAvail's executive leadership team, Ms. Seabaugh will lead the Company's financial operations. "Ramona's pharmacy industry expertise and extensive financial leadership experience will be invaluable in executing our strategy to drive operational and financial performance," said Ed Kilroy, President and Chief Executive Officer of MedAvail. "I am pleased to welcome Ramona to our team, as we continue to expand into new geographies and transform the pharmacy experience

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$MDVL
Financials

Live finance-specific insights

See more
  • MedAvail Reports Second Quarter 2023 Financial Results

    PHOENIX, Aug. 14, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the second quarter ended June 30, 2023. "During the second quarter, we were able to sustain the positive momentum that we have experienced since we began focusing on the immense market opportunity for our pharmacy technology in January of this year," said Mark Doerr, Chief Executive Officer of MedAvail. "Of note, we placed an additional two revenue generating MedCenters in the field, bringing our year-to-date total to six, and we reiterate our expectation that we will place 25 net new revenue generating MedCenters in

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • MedAvail Reports First Quarter 2023 Financial Results

    PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today reported financial results for the first quarter ended March 31, 2023. "During the first quarter, we made good progress toward our mission of becoming a leader in the development and manufacture of pharmacy technology solutions in the short time since we announced the sale of certain of our SpotRx assets to CVS in January," said Mark Doerr, Chief Executive Officer of MedAvail. "Our pipeline continues to grow, representing a mix of both new and existing partners, and we remain on track to achieve our previously stated goal of adding 25 net new dispe

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
  • MedAvail to Report First Quarter 2023 Financial Results on May 18

    PHOENIX, May 18, 2023 (GLOBE NEWSWIRE) -- MedAvail Holdings, Inc. (NASDAQ:MDVL) ("MedAvail"), an innovative pharmacy technology company, today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets. MedAvail management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Call and webcast details:Thursday, May 18th, 2023 @ 4:30pm ETInvestor dial-in: 1- 877-704-4453 (domestic) or 1-201-389-0920 (international)Conference ID: 13738987To access the Call me™ feature, which avoids having to wait for an operator, click here. The live a

    $MDVL
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

$MDVL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more